LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.

    En-Nasery-de Heer, Selma / Tromp, Vashti N M F / Westerman, Marjan J / Konings, Inge / Beckeringh, Jan Jacob / Boons, Christel L M / Timmers, Lonneke / Hugtenburg, Jacqueline G

    European journal of cancer care

    2022  Volume 31, Issue 6, Page(s) e13749

    Abstract: Objective: The use of adjuvant endocrine therapy (AET) after primary treatment of hormone receptor-positive breast cancer reduces the risk of recurrence and mortality. However, non-adherence is still common. Limited consideration has been given to how ... ...

    Abstract Objective: The use of adjuvant endocrine therapy (AET) after primary treatment of hormone receptor-positive breast cancer reduces the risk of recurrence and mortality. However, non-adherence is still common. Limited consideration has been given to how users deal with AET and the role of pharmaceutical care. Therefore, this study aims to obtain insight into the needs and wishes of women using AET regarding pharmaceutical care and eHealth.
    Methods: This is a qualitative explorative study comprising semi-structured interviews (n = 16) and a focus group (n = 5) among women who use or used AET after primary early-stage breast cancer (EBC) treatment using a thematic analysis approach.
    Results: Three themes emerged from the interviews and focus group: (1) experiences with AET use, (2) experiences with provided information and (3) needs and wishes regarding pharmaceutical care. Most women were highly motivated to use AET and indicated to have received useful information on AET. However, many expressed a strong need for more elaborate tailored and timely provided information on AET. They acknowledged the accessibility of pharmacists but reported that currently, pharmacists are hardly involved in AET care. Several women considered eHealth useful to obtain counselling and reliable information.
    Conclusion: Women need more comprehensive information and follow-up in primary setting after initial cancer treatments. A more elaborate role for the pharmacy and eHealth/mHealth, especially with regard to counselling on side effects and side effect management, could potentially improve pharmaceutical care.
    MeSH term(s) Female ; Humans ; Breast Neoplasms/drug therapy ; Chemotherapy, Adjuvant ; beta-Aminoethyl Isothiourea/therapeutic use ; Medication Adherence ; Pharmaceutical Services ; Patient Outcome Assessment ; Antineoplastic Agents, Hormonal/therapeutic use
    Chemical Substances beta-Aminoethyl Isothiourea (151-16-6) ; Antineoplastic Agents, Hormonal
    Language English
    Publishing date 2022-10-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 1303114-4
    ISSN 1365-2354 ; 0961-5423 ; 1360-5801
    ISSN (online) 1365-2354
    ISSN 0961-5423 ; 1360-5801
    DOI 10.1111/ecc.13749
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3347: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.

    Timmers, Lonneke / Beckeringh, Jan Jacob / van Herk-Sukel, Myrthe P P / Boven, Epie / Hugtenburg, Jacqueline G

    Pharmacoepidemiology and drug safety

    2012  Volume 21, Issue 10, Page(s) 1036–1044

    Abstract: Purpose: In recent years, the number of oral anticancer agents has increased substantially. Although these agents have quickly been incorporated in the treatment of a variety of malignancies, data on their incidence, prevalence and costs are lacking. ... ...

    Abstract Purpose: In recent years, the number of oral anticancer agents has increased substantially. Although these agents have quickly been incorporated in the treatment of a variety of malignancies, data on their incidence, prevalence and costs are lacking. The objective of the present study was to obtain insight into the use and the costs of oral anticancer agents (with Anatomical Therapeutic Chemical classification system (World Health Organisation) code L01) in the Netherlands between 2000 and 2008.
    Methods: Incidence and prevalence were determined using community pharmacy dispensing records obtained from the PHARMO Record Linkage System database. The data of costs were provided by the Genees- en hulpmiddelen Informatie Project of the Dutch Health Care Insurance Board (CVZ, Diemen, The Netherlands).
    Results: In the years 2000-2008, the use of oral anticancer agents has more than doubled from 64 to 140 users per 100 000 inhabitants. The increase is mainly caused by the prescription of capecitabine for various indications. There was a 50-fold rise in costs on oral anticancer agents from €2 m in 2000 to approximately €100 m in 2008. The share in the costs of tyrosine kinase inhibitors (TKIs) in 2008 was 67% (€70 m) with the oldest TKI, imatinib, having a share of more than 50% within the group of TKIs.
    Conclusions: The increased use of oral anticancer agents is mainly due to the frequent prescription of capecitabine. The increased costs are caused by the registration of a variety of TKIs, in particular imatinib. The costs of new agents with an orphan drug status are very high as compared with those of capecitabine, a newer agent for which there are alternative treatment options.
    MeSH term(s) Administration, Oral ; Antineoplastic Agents/economics ; Antineoplastic Agents/therapeutic use ; Benzamides ; Capecitabine ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/economics ; Deoxycytidine/therapeutic use ; Fluorouracil/analogs & derivatives ; Fluorouracil/economics ; Fluorouracil/therapeutic use ; Humans ; Imatinib Mesylate ; Neoplasms/drug therapy ; Netherlands ; Pharmacies/statistics & numerical data ; Piperazines/economics ; Piperazines/therapeutic use ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Pyrimidines/economics ; Pyrimidines/therapeutic use
    Chemical Substances Antineoplastic Agents ; Benzamides ; Piperazines ; Pyrimidines ; Deoxycytidine (0W860991D6) ; Capecitabine (6804DJ8Z9U) ; Imatinib Mesylate (8A1O1M485B) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2012-10
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1099748-9
    ISSN 1099-1557 ; 1053-8569
    ISSN (online) 1099-1557
    ISSN 1053-8569
    DOI 10.1002/pds.2225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3395: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.

    Boons, Christel C L M / VAN Tulder, Maurits W / Burgers, Jacobus A / Beckeringh, Jan Jacob / Wagner, Cordula / Hugtenburg, Jacqueline G

    Anticancer research

    2013  Volume 33, Issue 9, Page(s) 3553–3561

    Abstract: This review aims to provide insight into treatment of malignant pleural mesothelioma (MPM) considering effects on survival, quality of life (QoL) and costs, in order to determine the value of pemetrexed in MPM treatment. Cisplatin in combination with ... ...

    Abstract This review aims to provide insight into treatment of malignant pleural mesothelioma (MPM) considering effects on survival, quality of life (QoL) and costs, in order to determine the value of pemetrexed in MPM treatment. Cisplatin in combination with pemetrexed or raltitrexed increased survival in MPM, whereas vinorelbine and gemcitabine have led to good response rates. None of these appear to have any detrimental effect with respect to symptoms and global QoL. The cost-effectiveness of pemetrexed-cisplatin was found to be acceptable in advanced MPM compared with cisplatin, but raltitrexed-cisplatin was found to be a more cost-effective treatment option. This may also apply for gemcitabine and vinorelbine, since in contrast to pemetrexed, both agents can be obtained from generic manufacturers. As yet platinum-doublet therapy is the most effective palliative treatment of MPM. To provide a more cost-effective treatment approach for advanced MPM, further research should include randomized controlled trials comparing the recommended pemetrexed-cisplatin directly with platinum doublets with raltitrexed, gemcitabine, or vinorelbine.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Glutamates/therapeutic use ; Guanine/analogs & derivatives ; Guanine/therapeutic use ; Humans ; Mesothelioma/drug therapy ; Mesothelioma/physiopathology ; Pemetrexed ; Pleural Neoplasms/drug therapy ; Pleural Neoplasms/physiopathology ; Quality of Life
    Chemical Substances Antineoplastic Agents ; Glutamates ; Pemetrexed (04Q9AIZ7NO) ; Guanine (5Z93L87A1R)
    Language English
    Publishing date 2013-09
    Publishing country Greece
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top